SPOTLIGHT: FDA OKs expanded access for stem cell therapy


Osiris Therapeutics has won approval for an expanded access treatment program for Prochymal, making the Phase III stem cell therapy for graft-vs-host-disease available to children. Osiris release

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.